β2-Glycoprotein I, the playmaker of the antiphospholipid syndrome

Clinical Immunology

Volumn 112, Issue 2, 2004, Pages 161-168

  De Laat, H Bas ^a   Derksen, Ronald H W M ^a   De Groot, Philip G ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Haematology   (Netherlands)

Author keywords

Antiphospholipid syndrome; Autoimmune disease; Lupus; Thrombosis; 2 glycoprotein I

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY; GLYCOPROTEIN;

ANTIBODY DETECTION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; BINDING AFFINITY; BINDING SITE; CELL ACTIVATION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; THROMBOSIS; ANIMAL; CHEMISTRY; DIMERIZATION; IMMUNOLOGY; STANDARD;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; DIMERIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HUMANS;

EID: 3042706029     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.02.012     Document Type: Article

References (57)

1. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J., Zwaal R.F.A., Bevers E.M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a serum protein cofactor. Lancet. 335:1990;1544-1547
2. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactors(s) and differential diagnosis of autoimmune disease. Lancet. 336:1990;177-178
3. 2-glycoprotein I (Apolipoprotein H). Proc. Natl. Acad. Sci. U. S. A. 87:1990;4120
4. Wilson A.W., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R.V., Triplett D.A., Khamashta M.A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 42:1999;1309-1311
5. Roubey R.A.S. Treatment of the antiphospholipid syndrome. Curr. Opin. Rheumatol. 14:2002;238-242
6. Asherson R.A., Cervera R. The antiphospholipid syndrome: a syndrome in evolution. Ann. Rheum. Dis. 51:1992;147-150
7. Cooper R.C., Klemp P., Stipp C.J., Brink S. The relationship of anticardiolipin antibodies to disease activity in systemic lupus erythematosus. Br. J. Rheumatol. 28:1989;379-382
8. Petri M., Rheinschmidt M., Whiting-O'Keefe Q., Hellmann D., Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and cardiolipin antibody. Ann. Intern. Med. 106:1987;524-531
9. Derksen R.H.W.M., Bouma B.N., Kater L. The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand. J. Rheumatol. 16:1987;185-192
10. 2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin. Exp. Immunol. 115:1999;214-219
11. 2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun. 11:1989;425-429
12. 2- glycoprotein I by the human placenta. Placenta. 18:1997;302-410
13. 2- glycoprotein I in human plasma. Thromb. Haemostasis. 80:1998;791-798
14. 2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum. 42:1999;1655-1661
15. 2-glycoprotein I) which affect phospholipid binding. Hum. Mol. Genet. 6:1997;311-316
16. 2-glycoprotein I. FEBS Lett. 313:1992;193-197
17. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18:1999;5166-5174
18. 2-glycoprotein I: implication for phospholipid binding and the antiphospholipid syndrome. EMBO J. 18:1999;6228-6239
19. 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc. Natl. Acad. Sci. U. S. A. 1993;2141-2145
20. Wang S.X., Cai G.P., Sui S. The insertion of human apolipoprotein H into phospholipid membranes: a monolayer study. Biochem. J. 335:1998;225-232
21. 2-glycoprotein I) is crucial for cardiolipin binding. Eur. J. Biochem. 267:2000;1770-1776
22. 2-glycoprotein I-dependent alterations in membrane properties. Biochim. Biophys. Acta. 1509:2000;475-484
23. 2-glycoprotein I (apolipoprotein H) deficiency. Atherosclerosis. 55:1985;25-34
24. 2- glycoprotein I deficiency and the risk of thrombosis. Thromb. Haemostasis. 67:1992;649-653
25. Mann K.G., Lawson J.H. The role of the membrane in the expression of the vitamin K-dependent enzymes. Arch. Pathol. Lab. Med. 116:1992;1330-1340
26. 2-glycoprotein I complexes to lipid membranes. Biochemistry. 35:1996;13833-13842
27. 2-glycoprotein I complexes on phospholipid surfaces. Thromb. Haemostasis. 79:1998;79-86
28. 2-glycoprotein I antibody complexes. J. Biol. Chem. 276:2001;3060-3067
29. Rand J.H., Wu X.X., Andree H.A., Ross J.B., Russinova E., Gascon-Lema M.G., Calandri C., Harpel P.C. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood. 92:1998;1652-1660
30. 2-Glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells. Lupus. 7:1998;S44-S47
31. 2- glycoprotein I and anti-prothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood. 102:2003;2717-2723
32. 2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. J. Rheumatol. 25:1998;2131-2134
33. Bertolaccini M.L., Atsumi T., Escudero Contreras A., Khamashta M.A., Hughes G.R. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J. Rheumatol. 28:2001;2637-2643
34. Samarkos M., Asherson R.A., Loizou S. The clinical significance of IgA antiphospholipid antibodies. J. Rheumatol. 28:2001;694-697
35. 2- glycoprotein autoantibodies. Thromb. Haemostasis. 80:1998;393-398
36. 2-glycoprotein I fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol. Int. 18:1998;5-10
37. 2GPI in antibody binding. J. Immunol. 160:1998;3917-3923
38. 2-glycoprotein I recognized by anticardiolipin antibodies. Lupus. 7:1998;14-17
39. 2-glycoprotein I. Thromb. Haemostasis. 86:2001;590-595
40. 2-glycoprotein I antibodies from autoantibody and immunized sources. J. Autoimmun. 15:2000;91-96
41. 2- glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15542-15546
42. 2GPI to determine fine antigenic specificity of antiphospholipid autoantibodies. J. Immunol. 169:2002;7097-7103
43. Blank M., Shoenfeld Y., Cabilly S., Heldman Y., Fridkin M., Katchalski-Kater E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5168
44. Sheng Y., Sali A., Herzog H., Lahnstein J., Krilis S.A. Site-directed mutagenesis of recombinant human beta2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J. Immunol. 157:1996;3744-3751
45. 2-glycoprotein I: target antigen for antiphospholipid antibodies. Immunological and molecular aspects. Lupus. 7:1998;S5-S9
46. Jones D.S., Coutts S.M., Gamino C.A., Iverson G.M., Linnik M.D., Randow M.E., Ton-Hu H.T., Victoria E.J. Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response. Bioconjugate Chem. 10:1999;480-488
47. 2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb. Haemostasis. 88:2002;66-73
48. Roubey R.A., Eisenberg R.A., Harper M.F., Winfield J.B. "Anticardiolipin" autoantibodies recognize beta2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 1995;154954-154960
49. Matsuura E., Garashi Y., Yasuda T., Triplett D.A., Koike T. Anticardiolipin antibodies recognize beta2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 1994;179457-179462
50. 2GPI autoantibodies by ELISA. J. Autoimmun. 18:2002;289-297
51. 2-glycoprotein I autoantibodies require an antigen density threshold, consistent with divalent binding. Lupus. 12:2003;37-45
52. 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′ J. Biol. Chem. 278:2003;33831-33838
53. 2-glycoprotein I to human endothelial cells is mediated by annexin II. J. Biol. Chem. 275:2000;15541-15548
54. 2-glycoprotein I-phospholipid complex harbor a recognition site for the endocrytic receptor megalin. J. Clin. Invest. 102:1998;902-909
55. Raschi E., Testoni C., Bosiso D., Borghi M.O., Koike T., Mantovani A., Meroni P.L. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 101:2003;3495-3500
56. Gharavi A.E., Pierangeli S.S., Colden-Stanfield M., Liu X.W., Espinola R.G., Harris E.N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J. Immunol. 163:1999;2922-2927
57. 2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity to tissue factor pathway inhibitor. Thromb. Haemostasis. 84:2000;653-656